ArticleDrugs & aging2026

Real-World Persistence After Starting Bictegravir- or Dolutegravir-Based Regimens Among Adults Aged ≥50 Years with HIV in the United States.

Amanda M Kong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.